Alzheimer’s disease (AD) is
characterized by the continuous
decline of the cognitive abilities manifested due to the accumulation
of large aggregates of amyloid-beta 42 (Aβ42), the formation
of neurofibrillary tangles of hyper-phosphorylated forms of microtubule-associated
tau protein, which may lead to many alterations at the cellular and
systemic level. The current therapeutic strategies primarily focus
on alleviating pathological symptoms rather than providing a possible
cure. AD is one of the highly studied but least understood neurological
problems and remains an unresolved condition of human brain degeneration.
Over the years, multiple naturally derived small molecules, including
plant products, microbial isolates, and some metabolic byproducts,
have been projected as supplements reducing the risk or possible treatment
of the disease. However, unfortunately, none has met the expected
success. One major challenge for most medications is their ability
to cross the blood–brain barrier (BBB). In past decades, nanotechnology-based
interventions have offered an alternative platform to address the
problem of the successful delivery of the drugs to the specific targets.
Interestingly, the exciting interface of natural products and nanomedicine
is delivering promising results in AD treatment. The potential applications
of flavonoids, the plant-derived compounds best known for their antioxidant
activities, and their amalgamation with nanomedicinal approaches may
lead to highly effective therapeutic strategies for treating well-known
neurodegenerative diseases. In the present review, we explore the
possibilities and recent developments on an exciting combination of
flavonoids and nanoparticles in AD.